Garching (ots) - The ITM Group announced today that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next generation theranostic agent for Bone Targeted Radionuclide Therapy and Diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone ...
Garching (ots) - The ITM Group announced today that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) of the medicinal product EndolucinBeta, a radiopharmaceutical precursor. EndolucinBeta is not intended for direct use in patients but will be used for ...
Garching (ots) - - In-licensing of superior DOTA-Tyr3-octreotide - Pharmaceutical development for treatment of NETs - Excellent pharmacokinetic properties ITM Isotope Technologies Munich AG (ITM) today announced that it has entered into an exclusive licensing agreement with Progenics Pharmaceuticals Inc. for pharmaceutical development and commercialization of ...